Roche Holding AG stock news

Roche Holding AG stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-29 15:31:00 UTC#538717newconfirmednews

Global HER2 targeted therapies market projected to reach $11.75 billion in 2026, ResearchAndMarkets reports

yahooimportance 0.30trust 0.50Pfizer Inc. +0.20Roche Holding AG +0.20AstraZeneca PLC +0.20+2 entities

2026-10-28 06:01:43 UTC#526283duplicateconfirmednews

Roche launches VENTANA BAP1 (SP527) mesothelioma diagnostic test with FDA and IVDR approval

reutersimportance 0.30trust 0.90Roche Holding AG +0.30VENTANA BAP1 (SP527) +0.30U.S. Food and Drug Administration +0.20

2026-10-26 16:46:54 UTC#516126newreportednews

Roche develops experimental daily pill Gerardestrin for breast cancer prevention

bloombergimportance 0.40trust 0.60Roche Holding AG +0.40Gerardestrin +0.50Herceptin +0.20

2026-10-25 22:02:02 UTC#511938updateconfirmednews

Roche lung cancer drug divarasib extends survival by nearly six months in Phase III trial

seeking alphaimportance 0.50trust 0.70Roche Holding AG +0.60

2026-10-25 18:35:43 UTC#511616duplicateconfirmednews

Roche reports divarasib reduces lung cancer death risk by 44% in Phase III trial

reutersimportance 0.30trust 0.90Roche Holding AG +0.60divarasib +0.60

2026-10-25 18:29:27 UTC#511608duplicateconfirmednews

Roche reports Phase III Krascendo 1 trial data showing divarasib reduces lung cancer death risk by 44%

reutersimportance 0.40trust 0.90Roche Holding AG +0.60divarasib +0.60sotorasib -0.40+2 entities

2026-10-25 15:44:00 UTC#511399duplicateconfirmednews

Roche's divarasib shows 44% lower death risk in lung cancer trial, outperforming Amgen and Bristol Myers Squibb

dow_jonesimportance 0.40trust 0.90Roche Holding AG +0.60Revolution Medicines, Inc. 0Amgen Inc. -0.40+2 entities

2026-10-25 15:32:04 UTC#511389duplicateconfirmednews

Roche reports Phase III KRASCENDO 1 trial data for divarasib in KRAS G12C-mutated lung cancer

reutersimportance 0.60trust 0.90Roche Holding AG +0.80KRASCENDO 1 +0.50

2026-10-25 15:30:00 UTC#511387duplicateconfirmednews

Roche's divarasib reduces lung cancer death risk by 44% in Phase III trial, outperforming Amgen and BMS treatments

dow_jonesimportance 0.50trust 0.80Roche Holding AG +0.60Revolution Medicines, Inc. +0.20Amgen Inc. -0.40+2 entities

2026-10-24 08:37:38 UTC#509950duplicateconfirmednews

Swiss Market Index outperforms Euro Stoxx 50 in October as investors rotate into defensive stocks, Bloomberg reports

yahooimportance 0.30trust 0.60Swiss Market Index +0.30Roche Holding AG +0.60Novartis AG +0.60+2 entities

2026-10-23 17:49:31 UTC#508303duplicateconfirmednews

Novartis remibrutinib MS trial data shows 31-35% relapse reduction, missing analyst expectations of 45-60%

reutersimportance 0.40trust 0.90Novartis AG -0.50Sanofi 0Roche Holding AG +0.30+2 entities

2026-10-23 17:43:00 UTC#508247duplicateconfirmednews

Ionis and Roche report sefaxersen met primary endpoint with 43.1% proteinuria reduction in Phase 3 IgAN study

tradingviewimportance 0.40trust 0.70Ionis Pharmaceuticals, Inc. +0.60Roche Holding AG +0.60sefaxersen +0.60+1 entities

2026-10-23 17:37:00 UTC#508290duplicateconfirmednews

Roche and Ionis report Phase 3 IMAgINATION study data for sefaxersen in IgA nephropathy

yahooimportance 0.30trust 0.80Ionis Pharmaceuticals, Inc. +0.40Roche Holding AG +0.50sefaxersen +0.50+1 entities

2026-10-23 17:37:00 UTC#508242duplicateconfirmednews

Ionis Pharmaceuticals reports Roche's sefaxersen met primary endpoint in Phase 3 IgA nephropathy study

tradingviewimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. +0.60Roche Holding AG +0.60sefaxersen +0.60+1 entities

2026-10-23 17:33:07 UTC#508225newconfirmednews

Roche reports Sefaxersen achieved 43.1% reduction in proteinuria in Phase III IgA nephropathy trial

reutersimportance 0.60trust 0.90Roche Holding AG +0.60Sefaxersen +0.70IgA nephropathy 0

2026-10-23 17:16:00 UTC#508141duplicateconfirmednews

Novartis US shares decline as remibrutinib MS trial data shows lower efficacy than Roche rival

dow_jonesimportance 0.40trust 0.90Novartis AG -0.50Roche Holding AG +0.20Sanofi +0.20+2 entities

2026-10-23 17:01:00 UTC#508076duplicateconfirmednews

Novartis shares decline as remibrutinib MS trial data shows lower efficacy than Roche rival

dow_jonesimportance 0.40trust 0.80Novartis AG -0.40Roche Holding AG +0.20Sanofi +0.20+2 entities

2026-10-23 11:20:00 UTC#506178duplicateconfirmedanalysis

Deutsche Bank upgrades Roche to Buy, raises target to CHF500 citing positive giredestrant feedback

yahooimportance 0.40trust 0.70Roche Holding AG +0.60Deutsche Bank AG +0.20Emmanuel Papadakis 0+1 entities

2026-10-23 10:54:00 UTC#505944duplicateconfirmednews

Zymeworks and Roche partner on ZW209 lung cancer drug development in deal worth up to $813 million

dow_jonesimportance 0.40trust 0.80Zymeworks Inc. +0.60Roche Holding AG +0.30ZW209 +0.50

2026-10-23 10:39:00 UTC#505899duplicateconfirmednews

Zymeworks and Roche enter $813 million collaboration for lung cancer drug ZW209

dow_jonesimportance 0.30trust 0.80Zymeworks Inc. +0.60Roche Holding AG +0.40ZW209 +0.50